New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2014
08:58 EDTECYT, AZN, MRK, RHHBYAnalysts see Endocyte as potential target, Bloomberg says
Analysts at RBC believe Endocyte (ECYT) could see takeover interest from partner Merck (MRK), while Cowen thinks AstraZeneca (AZN) or Roche (RHHBY) could be potentially interested based on the strong results for the company's experimental cancer treatment, according to Bloomberg's "Real M&A" column.
News For ECYT;MRK;AZN;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 13, 2015
09:44 EDTMRKMerck makes $50M equity investment in Moderna under collaboration
Subscribe for More Information
08:08 EDTMRKEli Lilly, Merck enter collaborationa greement to evaluate Keytruda, compounds
Merck (MRK) and Eli Lilly and Company (LLY) announced an oncology clinical trial collaboration to evaluate the safety, tolerability and efficacy of KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with Lilly compounds in multiple clinical trials: Merck will conduct a Phase 2 study examining the combination of pembrolizumab with pemetrexed in first-line non-squamous, non-small cell lung cancer. This study is currently enrolling. Lilly will conduct a multiple-arm Phase 1/2 study examining the combination of ramucirumab with pembrolizumab in multiple tumors. This study is anticipated to begin in 2015. Lilly will conduct a Phase 1/2 study examining the combination of necitumumab with pembrolizumab in NSCLC. This study is anticipated to begin in 2015. The agreement is between Lilly and Merck, through a subsidiary. Additional details of the collaboration were not disclosed.
07:51 EDTRHHBYRoche deal positive, says Bernstein
Subscribe for More Information
06:29 EDTRHHBYRoche obtains rights to drug that strengthens antibiotics
Subscribe for More Information
06:18 EDTRHHBYSilicon Valley shuttle drivers looking to unionize, USA Today reports
Subscribe for More Information
January 12, 2015
16:32 EDTRHHBYOn The Fly: Closing Wrap
Stocks spent almost the entire session in negative territory as the continued slump in crude oil prices weighed on equities. As the price of crude searches for a bottom, analysts and investors are concerned about how the low prices may affect U.S. economic growth. It had been estimated that more than half of the expected growth in the S&P 500's earnings would come from the oil industry and the continued drop in oil prices may be wiping out the chances of earnings increasing from the prior quarter. The earnings season unofficially kicks off tonight when Alcoa (AA) reports its fourth quarter earnings. ECONOMIC EVENTS: In the U.S., no major economic data was released. WTI and Brent crude both suffered slides of 5% during the session, sending WTI oil below $46 and Brent near $47 per barrel. Of note, Goldman Sachs said it sees oil prices bottoming in Q2 of this year at $42 a barrel. Goldman lowered its Brent crude oil price estimate for 2015 to $50 a barrel from $84 and for 2016 onwards to $70 a barrel from $90. COMPANY NEWS: Shire (SHPG) shares trading in New York slipped $8.39, or 3.86%, to $209.10 after the company announced over this weekend that it struck a deal to acquire NPS Pharmaceuticals (NPSP) for $46 per share in cash, for a total consideration of approximately $5.2B. NPS shares gained $3.44, or 8.21%, to $45.35... Shares of flash storage provider SanDisk (SNDK) dropped $13.47, or 13.88%, to $83.57 after the company cut its revenue outlook for Q4 and added that non-GAAP gross margin for the quarter is expected to be approximately 45%, compared to the previously guided range of 47%-49%. "The lower revenue was primarily due to weaker than expected sales of retail and iNAND products," SanDisk explained. Micron (MU) fell $1.87, or 5.56%, to $31.66 following the warning from its peer. MAJOR MOVERS: Among the notable gainers was Foundation Medicine (FMI), whose shares surged $22.81, or 95.32%, to $46.74 after the company and Roche (RHHBY) announced that they will enter into a strategic collaboration. Roche will invest in Foundation as part of the deal, resulting in Roche owning a minimum of 52.4% and a maximum of 56.3% of Foundation Medicine on a fully diluted basis. Also higher was Build-A-Bear Workshop (BBW), which jumped $3.12, or 16.75%, to $21.75 after the toy company gave a fourth quarter revenue view that beat expectations. Among the noteworthy losers was Arrowhead Research (ARWR), which fell $2.16, or 23.84%, to $6.90 after announcing that the FDA verbally informed the company of a partial clinical hold on its study of ARC-520 in patients with chronic hepatitis B infection. Also lower were shares of Sarepta Therapeutics (SRPT), which dropped $2.04, or 14.62%, to $11.91 after the company provided data through Week 168 from its Phase IIb open-label extension study of eteplirsen in patients with Duchenne muscular dystrophy. INDEXES: The Dow fell 96.53, or 0.54%, to 17,640.84, the Nasdaq lost 39.36, or 0.84%, to 4,664.71, and the S&P 500 declined 16.55, or 0.81%, to 2,028.26.
12:46 EDTRHHBYOn The Fly: Midday Wrap
Subscribe for More Information
08:37 EDTMRK, RHHBY, AZNShire deal suggests most biotech companies in play, says JMP Securities
After Shire (SHPG) agreed to buy NPS Pharmaceuticals (NPSP), JMP Securities says the deal indicates that most biotech companies are in play, particularly those with worldwide rights to their products for well-defined patient populations. The firm expects investors to speculate all week about potential new targets in the space. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07:21 EDTMRKEBD Group to hold a conference
Subscribe for More Information
07:07 EDTMRKMerck sees NDA submission for Hepatitis C combination regimen in 1H15
Subscribe for More Information
07:05 EDTMRKMerck says targeted cost savings on track to be realized by end 2015
Subscribe for More Information
07:04 EDTMRKMerck sees NDA submission for Hepatitis C combination regimen in 1H15
Subscribe for More Information
07:03 EDTMRKMerck says targeted cost savings on track to be realized by end 2015
Subscribe for More Information
06:53 EDTMRKMerck to speed up plans for drug submission, WSJ says
Merck is speeding up its plans to submit new drugs for lung cancer and hepatitis C for regulatory approval, reports the Wall Street Journal. The company will file an application with the FDA around the mid-2015 to expand the use of Keytruda, the Journal adds. Reference Link
06:40 EDTRHHBYFoundation Medicine to host conference call
Subscribe for More Information
06:22 EDTMRKWHO approves 2 ebola vaccines to enter West Africa trials, Financial Times says
Subscribe for More Information
05:36 EDTAZNQIAGEN announces regulatory registration of lung cancer companion diagnostic
Subscribe for More Information
05:25 EDTRHHBYFoundation Medicine up 100.6% following transaction with Roche
05:22 EDTRHHBYFoundation Medicine announces strategic collaboration with Roche
Subscribe for More Information
05:21 EDTRHHBYRoche to acquire majority interest in Foundation Medicine for $50 per share
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use